PMZ-2123 prevents the development of neurological complications in diabetic ketoacidosis patients.
Intravenous administration of PMZ-2123 prevents the development of cerebral edema in patients of diabetic ketoacidosis. Efficacy has been demonstrated in animal models of diabetic ketoacidosis.
Patents issued in United States, Japan, European Union, Australia, China and Canada.
PMZ-2123 has been safely used in humans as an investigational agent (NCT00115583; NCT00915070; NCT01658410).
Diabetic Ketoacidosis (PMZ-2123)